Drug Channels Institute

Name

Drug Channels Institute

Legal name

HMP Omnimedia, LLC

Website

https://drugchannelsinstitute.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Research and Education

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292), Pharmacies and Drug Retailers (45611)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Channel & Trade Strategy (Gross-to-Net, Distribution Economics) (HLAIAKAI)

akta.pro secondary industries

Pharmacy Benefit Management (PBM) & Pharmacy Network Administration (HLAFALAI), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical economics research
• Drug distribution analysis
• Pharmacy industry education
• PBM market intelligence
• Pharmaceutical wholesale reports

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Industry Reports: Sale of downloadable PDF industry reports with multiple license tiers. Reports cover pharmaceutical wholesalers, specialty distributors, pharmacies, and PBMs. License types include single-user, department/team, and corporate licenses. Some reports include optional PowerPoint exhibit files.
2. E-Learning Modules: Subscription-based e-learning modules covering pharmaceutical economics topics including PBMs, wholesalers, specialty pharmacy, retail pharmacies, and drug distribution. Offered via site-wide licenses or hosted Moodle-based learning environments.
3. Webinars: Periodic live video webinars on critical industry topics delivered by Dr. Adam J. Fein. Sold per viewing device with team discounts available. Single events priced at $420/device; annual series of three events at $1,080/device.
4. Keynote Speaking: Keynote presentations by Dr. Adam J. Fein at industry conferences and private corporate events. Selective engagements for planning sessions, executive briefings, and board presentations.
5. Leadership Forum: Annual executive conference (Drug Channels Leadership Forum) held at JW Marriott Miami Turnberry Resort and Spa. By-invitation event featuring fireside chats with industry executives and panel discussions on drug channel strategic issues.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Drug Channels Institute produces licensed industry research reports, interactive e-learning modules, live webinars, executive conferences, and keynote presentations covering U.S. pharmaceutical economics, drug pricing and reimbursement, pharmacy benefit managers (PBMs), and pharmaceutical wholesale and specialty distribution. The offerings are sold on a B2B basis to pharmaceutical manufacturers, wholesalers, pharmacies, hospitals, PBMs, healthcare investors, and academic institutions.

Product overview

Drug Channels Institute (DCI) offers a platform of specialized management education products for the pharmaceutical industry. The core offerings include two flagship annual Industry Reports (the 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers and the 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors) which provide comprehensive economic analyses of the drug distribution system. Supporting these reports are six E-Learning Modules covering topics from PBMs and wholesalers to specialty pharmacy and drug reimbursement flows. Additional products include the Drug Channels Website (DrugChannels.net blog), Keynote Speaking engagements by Dr. Adam Fein, periodic Webinars, and the annual Drug Channels Leadership Forum executive conference. These offerings work together to help pharmaceutical manufacturers, wholesalers, pharmacists, hospital executives, PBMs, policy analysts, and investors understand pharmaceutical economics and the complex U.S. pharmacy distribution system.

Differentiator

Problem solved

Functional benefit

Brands

• Drug Channels Blog: Popular blog covering pharmaceutical economics and drug distribution analysis, led by Adam J. Fein, Ph.D.
• The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
• The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
• E-Learning Modules
• Drug Channels Leadership Forum
• Drug Channels Webinars

Products and services

• The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers Comprehensive annual 566-page economic report analyzing the U.S. drug pricing, reimbursement, and dispensing system. Covers pharmacy dispensing channels, PBMs, benefit design, drug pricing, manufacturer rebates, Medicare Part D, Medicaid, 340B Drug Pricing Program, and industry trends, featuring 270 proprietary data exhibits. Sold to pharmaceutical manufacturers, wholesalers, pharmacies, PBMs, hospitals, and investors.
• The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors Comprehensive 413-page PDF report examining the commercial, political, financial, and legal forces driving change in the U.S. pharmaceutical wholesale distribution industry. Covers the Big Three wholesalers (Cencora, Cardinal Health, McKesson) and includes 187 proprietary data exhibits. Sold at single-user, department/team, and corporate license tiers.
• E-Learning Modules Suite of six interactive e-learning modules covering pharmaceutical economics topics including PBMs, pharmaceutical wholesalers, provider-administered specialty drugs, retail/mail/specialty pharmacies, specialty pharmacy business, and drug distribution/reimbursement flows. Delivered with animated graphics and professional narration via site-wide licenses on customer LMS or DCI's hosted Moodle environment.
• Drug Channels Webinars Periodic live video webinars on crucial industry topics prepared and delivered by Adam J. Fein, Ph.D. via Zoom. Includes unlimited viewers from a single location, downloadable slide PDFs, and Q&A. Sold per viewing device with team discounts.
• Drug Channels Leadership Forum Annual by-invitation executive forum featuring candid fireside chats, panel discussions, and networking on strategic issues shaping the U.S. pharmaceutical ecosystem. Held at JW Marriott Miami Turnberry Resort with sponsorship opportunities.
• Keynote Speaking Engagements Paid keynote speaking engagements by Adam J. Fein, Ph.D., delivering content-rich presentations on pharmaceutical economics and drug distribution to associations, biopharmaceutical manufacturers, healthcare organizations, and technology companies, including planning sessions, executive briefings, and board presentations.

Quantifiable outcome

• 2025 report examines $683 billion prescription dispensing market
• +1 more outcomes

Named customers8 records

Segments1 record

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• HMP GlobalcoreStrategic or Co-development PartnerHMP Global is the omnichannel market leader in healthcare events, education, and insight. Drug Channels Institute is a subsidiary (an HMP Global Company) that links Dr. Fein's expertise with DCI's industry learning tools. HMP Global provides infrastructure for DCI's events including the Drug Channels Leadership Forum.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Artemetrx: Artemetrx specializes in specialty drug economics and pharmacy benefit analytics, mirroring DCI's specialty-distribution and provider-administered drug modules with a more data-software delivery model.
• Clarivate (Decision Resources Group): Clarivate's DRG unit sells syndicated pharma market research, forecasting, and intelligence reports to manufacturers, payers, and providers — directly overlapping DCI's report-based, subscription-licensed research model in pharma economics.
• The Moran Company: The Moran Company produces healthcare economic research, particularly on hospital and post-acute reimbursement — a smaller, niche B2B healthcare economics research firm structurally similar to DCI.
• Evaluate Pharma (Norstella): Evaluate Pharma provides commercial drug forecasting and industry intelligence to pharma and financial clients; its subscription data products compete for the same enterprise budget that DCI's annual reports command.
• Avalere Health: Avalere produces healthcare policy and market-access research for pharma, providers, and payers — a comparable B2B research/consulting model targeting the same U.S. drug-channel buyer personas DCI serves.
• Pharmaceutical Strategies Group (PSG): PSG delivers PBM consulting, 340B program advisory, and pharmacy benefit analytics — overlapping DCI's core PBM and 340B educational and research content with a practitioner-services angle.

Broad incumbents

• IQVIA: IQVIA is the dominant global pharma data, analytics, and consulting franchise; its broader portfolio competes for the same enterprise drug-channel budgets as DCI but with proprietary datasets and global scale DCI does not have.
• ZS Associates: ZS is a large pharma and healthcare consulting firm with proprietary analytics and market-access practices that overlap with DCI's buyer use cases around distribution strategy and channel economics.
• McKinsey & Company (Pharma Practice): McKinsey's Pharmaceuticals & Medical Products practice sells strategic advisory and bespoke research to the same drug-channel executives that purchase DCI reports, albeit at project-fee scale orders of magnitude larger than DCI's.
• MJH Life Sciences: MJH is a healthcare events, education, and media company and a direct competitive counterpart to DCI's parent HMP Global; both monetize clinician and executive audiences through similar events, publications, and continuing-education products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drug Channels Institute